文章基本信息

标题：Author Correction: mTORC1 Maintains the Tumorigenicity of SSEA-4 ⁺ High-Grade Osteosarcoma
本地全文：下载
作者：Wu Zhang ; Meng-Lei Ding ; Jia-Nian Zhang 等
期刊名称：Scientific Reports
电子版ISSN：2045-2322
出版年度：2021
卷号：11
DOI：10.1038/s41598-021-00930-2
语种：English
出版社：Springer Nature
摘要：Correction to: Scientific Reports 10.1038/srep09604, published online 08 April 2015 This Article contains an error in Figure 6, where the incorrect image was used for Figure 6c. The correct Figure 6 and its accompanying legend appear below. Figure 6 Terminal differentiation induction by mTOR-inactivation decreases SSEA-4 + TICs in vivo. ( a) SSEA-4 + cells (1–50 × 10 5) from the different resources as indicated were subcutaneously inoculated into NOD/SCID mice. The oral administration of PBS (filled box) or 5 mg/kg RAD001 (filled circle) commenced 2 days later. Tumor volumes are shown as the means ± SDs, n = 3–5. ( b, c) Representative images of whole-body ( b) or lung metastasis ( c) bioluminescence 4 weeks following subcutaneous ( b) or tail vein injection ( c) of 1 × 10 5 PBS- or RAD001-treated SSEA-4 + Well5 cells (as in ( a)) into NOD/SCID mice. ( d) Two representative tissue samples retrieved from the PBS-treated and RAD001-treated groups, respectively. ( e) Immunohistochemical staining of p-S6, SSEA-4, or OCN in xenografts retrieved from the PBS-or RAD001-treated group, as in ( a, b). Scale bars represent 100 μm. HE: hematoxylin–eosin. ( f) Secondary tumorigenic xenograft formation of tumor tissue or cells after post-PBS or -RAD001 treatment, as in ( a, b) (upper panel). Secondary tumorigenic xenografting rates (n/n) are summarized in the bottom table ( P < 0.01).